<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01933360</url>
  </required_header>
  <id_info>
    <org_study_id>W500M</org_study_id>
    <nct_id>NCT01933360</nct_id>
  </id_info>
  <brief_title>Misoprostol for Cervical Priming Prior to Vacuum Aspiration</brief_title>
  <official_title>Sublingual Versus Vaginal Misoprostol for Cervical Dilatation 1 or 3 Hours Prior to Surgical Abortion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karolinska Institutet</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Karolinska Institutet</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Despite of the widespread use, and extensive studies, the optimal route of administration of
      misoprostol before surgical abortion remains to be defined. Following administration of 400
      mcg vaginally as per clinical guidelines, the time for optimal priming seems to be 3 hours,
      but the longer the interval the greater the risk or bleeding and expulsion of the uterine
      contents before the surgical evacuation. Sublingual administration seems to give adequate
      plasma concentration and cervical priming faster than oral or vaginal administration. This
      may allow a shorter waiting time with maintained efficacy, less side effects and logistic
      advantages.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Force needed for cervical dilatation</measure>
    <time_frame>Measured at surgery</time_frame>
    <description>Cervical dilation is evaluated at surgery using Hulka dilators connected to a tonometer. Force and time needed for the dilatation is recorded by the tonometer</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cervical diameter</measure>
    <time_frame>Measured at surgery</time_frame>
    <description>Cervical dilation is evaluated at surgery using Hulka dilators connected to a tonometer.The largest dilator that can pass through the inner cervical os without any resistance corresponds to the presurgical cervical diameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events</measure>
    <time_frame>Up to surgery</time_frame>
    <description>Any side effects or symptoms such as nausea, vomiting, uterine cramps, expulsion, bleeding, rash, chills, blood pressure etc are recorded continuously from misoprostol administration until to surgery</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">184</enrollment>
  <condition>First Trimester Pregnancy</condition>
  <condition>Surgical Termination of Pregnancy</condition>
  <arm_group>
    <arm_group_label>Misoprostol sublingual,1h</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Administration of misoprostol sublingually 1h prior to surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Misoprostol sublingual. 3h</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Administration of misoprostol sublingually 3h prior to surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Misoprostol vaginal,1h</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Administration of misoprostol vaginally 1h prior to surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Misoprostol vaginal,3h</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Administration of misoprostol vaginally 3h prior to surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Misoprostol sublingual, 1h</intervention_name>
    <description>Misoprostol is administered sublingually 1 hour prior to surgical termination of early pregnancy</description>
    <arm_group_label>Misoprostol sublingual,1h</arm_group_label>
    <other_name>Misoprostol (Cytotec)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo sublingual,1h</intervention_name>
    <description>Placebo for misoprostol is administered sublingually 1 hour prior to surgical termination of early pregnancy</description>
    <arm_group_label>Misoprostol vaginal,1h</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Misoprostol sublingual, 3h</intervention_name>
    <description>Misoprostol is administered sublingually, 3 hours prior to surgical termination of early pregnancy</description>
    <arm_group_label>Misoprostol sublingual. 3h</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Misoprostol vaginal, 1h</intervention_name>
    <description>Misoprostol is administered vaginally 1 hour prior to surgical termination of early pregnancy</description>
    <arm_group_label>Misoprostol vaginal,1h</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Misoprostol vaginal, 3h</intervention_name>
    <description>Misoprostol is administered vaginally 3 hours prior to surgical termination of early pregnancy</description>
    <arm_group_label>Misoprostol vaginal,3h</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo sublingual, 3h</intervention_name>
    <description>Placebo for misoprostol is administered sublingually 3 hours prior to surgical termination of early pregnancy</description>
    <arm_group_label>Misoprostol vaginal,3h</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo vaginal, 1h</intervention_name>
    <description>Placebo for misoprostol is administered vaginally 1 hour prior to surgical termination of early pregnancy</description>
    <arm_group_label>Misoprostol sublingual,1h</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo vaginal, 3h</intervention_name>
    <description>Placebo for misoprostol is administered vaginally 3 hours prior to surgical termination of early pregnancy</description>
    <arm_group_label>Misoprostol sublingual. 3h</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  women opting for first trimester surgical abortion

          -  nulliparous

          -  able and willing to provide informed consent

        Exclusion Criteria:

          -  unwilling to participate,

          -  unable to communicate in Swedish and English and

          -  minors (i.e. women &lt; 18 years of age),

          -  contraindications to misoprostol

          -  women with pathological pregnancies
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kristina Gemzell Danielsson, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Karolinska Institutet</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Karolinska University Hospital</name>
      <address>
        <city>Stockholm</city>
        <zip>17176</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>August 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 25, 2013</study_first_submitted>
  <study_first_submitted_qc>August 28, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 2, 2013</study_first_posted>
  <last_update_submitted>August 13, 2014</last_update_submitted>
  <last_update_submitted_qc>August 13, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 15, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Karolinska Institutet</investigator_affiliation>
    <investigator_full_name>Kristina Gemzell Danielsson</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Misoprostol</keyword>
  <keyword>First trimester pregnancy</keyword>
  <keyword>Surgical abortion</keyword>
  <keyword>Cervical priming</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Misoprostol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

